Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial.
Nalinie Joharatnam-HoganDuaa HatemFay H CaffertyGiovanna PetrucciDavid A CameronAlistair RingHoward G KynastonDuncan C GilbertRichard H WilsonRichard A HubnerDaniel E B SwinsonSiobhan ClearyAlex RobbinsMairead MacKenzieMartin W G Scott-BrownSharmila SothiLesley K DawsonLisa M CapaldiMark ChurnDavid CunninghamVincent KhooAnne C ArmstrongNicola L AinsworthGail HoranDuncan A WheatleyRussell MullenFiona J LoftsAxel WaltherRebecca A HerbertsonJohn D EatonAnn O'CallaghanAndrew EichholzMohammed M KagziDaniel M PattersonKrishna NarahariJennifer BradburyZuzana StokesAzhar J RizviGeorgina A WalkerVictoria L KuneneNarayanan SrihariAleksandra Gentry-MaharajAngela MeadeCarlo PatronoBianca RoccaRuth E LangleyPublished in: British journal of cancer (2023)
Persistently increased thromboxane biosynthesis was detected after radical cancer therapy, particularly in colorectal and gastro-oesophageal patients. Thromboxane biosynthesis should be explored further as a biomarker of active malignancy and may identify patients likely to benefit from aspirin.
Keyphrases
- end stage renal disease
- low dose
- ejection fraction
- newly diagnosed
- chronic kidney disease
- cancer therapy
- prognostic factors
- cardiovascular events
- peritoneal dialysis
- clinical trial
- randomized controlled trial
- cardiovascular disease
- coronary artery disease
- acute coronary syndrome
- study protocol
- patient reported outcomes
- phase iii